Browse HACE1

Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, Golgi stack membrane. Cytoplasm. Endoplasmic reticulum. Note=A significant portion localizes to the endoplasmic reticulum. Targeted to Golgi membrane via its interaction with Rab proteins.
Domain PF12796 Ankyrin repeats (3 copies)
PF00632 HECT-domain (ubiquitin-transferase)
Function

E3 ubiquitin-protein ligase involved in Golgi membrane fusion and regulation of small GTPases. Acts as a regulator of Golgi membrane dynamics during the cell cycle: recruited to Golgi membrane by Rab proteins and regulates postmitotic Golgi membrane fusion. Acts by mediating ubiquitination during mitotic Golgi disassembly, ubiquitination serving as a signal for Golgi reassembly later, after cell division. Specifically interacts with GTP-bound RAC1, mediating ubiquitination and subsequent degradation of active RAC1, thereby playing a role in host defense against pathogens. May also act as a transcription regulator via its interaction with RARB.

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0007030 Golgi organization
GO:0007265 Ras protein signal transduction
GO:0016601 Rac protein signal transduction
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0061025 membrane fusion
GO:0070936 protein K48-linked ubiquitination
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0017016 Ras GTPase binding
GO:0017048 Rho GTPase binding
GO:0017137 Rab GTPase binding
GO:0019787 ubiquitin-like protein transferase activity
GO:0031267 small GTPase binding
GO:0048365 Rac GTPase binding
GO:0051020 GTPase binding
Cellular Component GO:0005795 Golgi stack
GO:0031984 organelle subcompartment
GO:0031985 Golgi cisterna
GO:0032580 Golgi cisterna membrane
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HACE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HACE1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HACE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0140.953
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0580.944
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0150.98
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0190.946
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0630.97
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1220.954
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0390.894
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0060.996
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0140.991
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1660.838
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3280.144
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1260.0883
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HACE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HACE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HACE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HACE1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HACE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HACE1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HACE1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHACE1
NameHECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1
Aliases KIAA1320; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; E3 ubiquitin-protein liga ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HACE1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.